Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer

Vishwajith Sridharan1,2, Danielle N Margalit1, Stephanie A Lynch1, Mariano Severgnini3, Jun Zhou3, Nicole G Chau4, Guilherme Rabinowits4, Jochen H Lorch4, Peter S Hammerman4, F Stephen Hodi3,4, Robert I Haddad4, Roy B Tishler1 and Jonathan D Schoenfeld1 1Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Center, Boston, MA, USA; 2Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, USA; 3Center for Immuno-oncology, Dana-Farber Cancer Institute, Boston, MA, USA and 4Department of Medical Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Center, Boston, MA, USA